Hemorrhagic Malignant Pleural Effusion: Diagnosis, Survival Rate, and Response to Talc Pleurodesis
- 14 November 2020
- journal article
- research article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 12 (1) , 54-60
Abstract
Hemorrhagic malignant pleural effusion (HMPE) is diagnosed in 47–50% of all malignant pleural effusions (MPE). The aim of this study is to evaluate clinical, radiological, and morphological manifestations of HMPE and results of talc pleurodesis treatment. This is a retrospective review of the medical charts of 135 MPE patients which consists of HMPE group (42 patients) and simple MPE group (63 patients) (median age 67.9 years; 43 males, 62 females). In HMPE vs. simple MPE patients, pronounced dyspnea (100% vs. 88.9%, P = 0.024), chest pain (59.5% vs. 60.3%, P = 1), general deterioration (78.6% vs. 74.6%, P = 0.411) combined with large pleural effusion (81% vs. 50.8%, P = 0.001), and thickening of parietal pleura (73.8% vs. 68.3%, P = 0.349), all were more specific for HMPE. Cytological examination of HMPE showed more malignant pleural fluid cells (81% vs. 63.5%, P = 0.043). Histological examination revealed poorly differentiated types of tumors in 69.05% of HMPE (bronchogenic 33.33%, intestinal 16.67%, breast 14.3%) vs. 7.94% of simple MPE. In 19 HMPE vs. 0 simple MPE patients, thoracoscopy showed bleeding nodules (94.7%) on thickened parietal pleura (84.2%). Pleurodesis with talc by slurry (59%) and poudrage (41%) was less effective in HMPE than in simple MPE patients after 1 month (failed response; 33.3% vs. 21.6, P = 0.019), 3 months (42.9% vs. 25.7%, P = 0.017), and 6 months (42.9% vs. 21.7%, P = 0.035). Survival in HMPE was significantly lower (3.06 months vs. 5.37 months, P = 0.0005). HMPE has more severe clinical, laboratory, radiological, and endoscopic manifestations due to a more poorly differentiated malignant process. Talc pleurodesis was less effective in HMPE, and survival was poor.Keywords
This publication has 24 references indexed in Scilit:
- Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysisExperimental and Therapeutic Medicine, 2012
- Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancerJournal of Cardiothoracic Surgery, 2010
- Emerging paradigms in the management of malignant pleural effusionsRespiratory Medicine, 2008
- Cells in pleural fluid and their value in differential diagnosisJournal of Cytology, 2008
- Talc poudrage versus talc slurry in the treatment of malignant pleural effusion.European Journal of Cardio-Thoracic Surgery, 2006
- Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesisInteractive CardioVascular and Thoracic Surgery, 2006
- BTS guidelines for the investigation of a unilateral pleural effusion in adultsThorax, 2003
- Talc pleurodesis: Talc slurry versus thoracoscopic talc insufflation in a porcine modelThe Annals of Thoracic Surgery, 1996
- Diagnosis and management of malignant pleural effusionsThe American Journal of Surgery, 1995
- Malignant pleural effusion.BMJ, 1968